Clinical Trials
4
Active:0
Completed:1
Trial Phases
2 Phases
Phase 1:3
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (75.0%)Phase 2
1 (25.0%)Study of NEROFE, a Novel Hormone-Peptide in Adult Patients With Advanced MDS and AML
- First Posted Date
- 2020-04-28
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- Immune System Key Ltd
- Target Recruit Count
- 18
- Registration Number
- NCT04365179
- Locations
- 🇺🇸
University of Miami Hospital and Clinics / Sylvester Comprehensive Cancer Center, Miami, Florida, United States
Safety and Efficacy of IV Nerofe™ Followed by Doxorubicin, In Metastatic Ovarian Cancer and Triple Negative Breast Cancer
Phase 1
Withdrawn
- Conditions
- Triple Negative Breast CancerMetastatic Ovarian Cancer
- First Posted Date
- 2018-08-16
- Last Posted Date
- 2021-10-26
- Lead Sponsor
- Immune System Key Ltd
- Registration Number
- NCT03634150
- Locations
- 🇮🇱
Oncologic Institue, Kaplan, Reẖovot, Israel
A Phase 2a, Open-Label, Two Stage Study of Nerofe or Nerofe With Doxorubicin in Subjects With AML or MDS
Phase 2
Withdrawn
- Conditions
- Acute Myelogenous LeukemiaMyelodysplastic Syndromes
- Interventions
- First Posted Date
- 2017-02-23
- Last Posted Date
- 2020-07-31
- Lead Sponsor
- Immune System Key Ltd
- Registration Number
- NCT03059615
- Locations
- 🇮🇱
Rabin Medical Center, Petach Tikva, Israel
🇮🇱Kaplan Medical Center, Reẖovot, Israel
Phase 1 Trial of Intravenously Administered Nerofe™ in Subjects With Advanced Malignancies
- First Posted Date
- 2012-09-24
- Last Posted Date
- 2018-06-25
- Lead Sponsor
- Immune System Key Ltd
- Target Recruit Count
- 23
- Registration Number
- NCT01690741
- Locations
- 🇮🇱
Kaplan Medical Center, Rehovot, Israel
News
No news found